| Biomarker ID | 1145 |
| PMID | 23813660 |
| Year | 2013 |
| Biomarker | SLC14A1; LOC642587; TRIM29; CYP3A5; TP73L; SNAI2; PIK3R1; KRT5; NPAL3; FGFR2; CSTA; CAPG; ITGA2; FER1L3; MEIS2; LGALS3BP; GPRC5B; NEFH; GSTM2; S100A16; MME; EVA1; KRT23; ADD3; GSTP1; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 31 PC patients and 17 patients with benign prostatic hyperplasia were included in the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SLC14A1, LOC642587, TRIM29, CYP3A5, TP73L, SNAI2, PIK3R1, KRT5, NPAL3, FGFR2, CSTA, CAPG, ITGA2, FER1L3, MEIS2, LGALS3BP, GPRC5B, NEFH, GSTM2, S100A16, MME, EVA1, KRT23, ADD3, GSTP1 |